Posted by Michael Wonder on 18 Oct 2023
AbbVie's Epkinly (epcoritamab) receives Health Canada authorisation with conditions as the first and only subcutaneous bi-specific antibody to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma
17 October 2023 - AbbVie today announced that Epkinly (epcoritamab) has received Health Canada authorisation with conditions.
It is the first and only subcutaneous T-cell engaging bi-specific antibody for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL transformed from indolent lymphoma, high grade B-cell lymphoma, primary mediastinal B-cell lymphoma or follicular lymphoma grade 3B after two or more lines of systemic therapy and who have previously received or are unable to receive CAR-T cell therapy
